Welcome to our dedicated page for Smith & Nephew SEC filings (Ticker: SNN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Smith & Nephew plc (SNN) regulatory disclosures filed with the U.S. Securities and Exchange Commission, primarily through Form 6-K current reports for foreign private issuers. These filings give investors structured insight into the company’s capital structure, strategy, acquisitions and transactions by senior management.
Smith & Nephew uses Form 6-K to report a range of information, including announcements about its RISE strategy and related 2028 financial targets for revenue growth, trading profit, free cash flow and post-tax return on invested capital. Other 6-Ks detail portfolio rationalisation plans, guidance for upcoming financial years, and information on Capital Markets Day events where management presents strategic and product updates.
Filings also include voting rights and capital disclosures, setting out the total issued share capital, treasury shares and the number of voting rights that shareholders should use when assessing notification thresholds under applicable transparency rules. Separate TR-1 notifications, reproduced within 6-Ks, report major holdings changes by institutional investors such as BlackRock, Inc., including the percentage of voting rights attached to shares and through financial instruments.
Additional 6-K reports provide Market Abuse Regulation-compliant notifications of transactions by persons discharging managerial responsibilities (PDMRs) and persons closely associated with them. These cover purchases of ordinary shares and American Depositary Shares, participation in dividend reinvestment and employee stock purchase plans, and vesting of restricted share awards, giving a view of insider dealing activity around SNN securities.
Investors can also find transaction-related disclosures, such as the acquisition of Integrity Orthopaedics and its Tendon Seam™ rotator cuff repair technology, including headline deal terms, strategic rationale within the Sports Medicine portfolio and comments from management. By combining real-time EDGAR updates with AI-powered summaries, this page helps users navigate Smith & Nephew’s 6-Ks, understand the implications of voting rights and insider transactions, and quickly grasp the strategic content of narrative announcements without reading every paragraph in full.
Smith & Nephew plc reported a manager-related share transaction under UK Market Abuse Regulation. KAGAMA Family Investments, LP, a person closely associated with Independent Non-Executive Director Garheng Kong, purchased 3,000 Smith & Nephew American Depositary Shares at $33.9773 per ADS on the New York Stock Exchange on 2025-11-06.
This is a routine disclosure of dealings by persons discharging managerial responsibilities or their closely associated persons.
Smith & Nephew plc filed a Form 6-K reporting a PDMR share purchase. Chief Corporate Strategy & Development Officer Ajay Dhankhar bought 18,460 Smith & Nephew American Depositary Shares at $32.5792 per ADS on the New York Stock Exchange on November 6, 2025.
This filing is a routine disclosure under UK Market Abuse Regulation, documenting a senior executive’s transaction in the company’s ADSs. It records an open-market purchase by a person discharging managerial responsibilities and does not reflect an issuance by the company.
Smith+Nephew (NYSE: SNN) announced that Thérèse Esperdy will join the Board as an independent Non‑Executive Director and Senior Independent Director designate effective 1 December 2025. She is expected to succeed Angie Risley as Senior Independent Director following the Company’s AGM in May 2026.
Esperdy will serve on the Nomination & Governance and Remuneration Committees. Her background includes chairing Imperial Brands plc, board service at Moody’s Corporation, and senior leadership roles at J.P. Morgan. The company noted that no disclosure obligations arise under UKLR 6.4.8 R for this appointment.
Smith+Nephew reported Q3 2025 revenue of $1,501 million, up 5.0% on an underlying basis and 6.3% reported, with a 130bps currency tailwind. Orthopaedics grew 4.1% underlying as strong US Hip Implants offset softer US Knee Implants. Sports Medicine & ENT rose 5.1% underlying, with growth outside China and VBP headwinds easing. Advanced Wound Management increased 6.0% underlying, led by double‑digit gains in Advanced Wound Bioactives.
The company reaffirmed its full‑year outlook for around 5.0% underlying revenue growth and a trading profit margin of 19.0%–20.0%. Guidance for free cash flow was raised to around $750 million (previously more than $600 million), and the $500 million share buyback was completed. Management noted an expected net tariff impact of $15–$20 million in 2025. The US grew 5.5% underlying in the quarter; Advanced Wound Bioactives rose 12.2% underlying. Capital Markets Days are set for 8 and 11 December 2025, with full‑year results on 2 March 2026.
Smith+Nephew reported third-quarter revenue of $1,501 million, up 6.3% reported and 5.0% underlying, with a 130bps foreign exchange tailwind. Growth was broad-based: Orthopaedics underlying up 4.1%, Sports Medicine & ENT up 5.1%, and Advanced Wound Management up 6.0%. The US grew 5.5% on both a reported and underlying basis.
The company reaffirmed full-year guidance for underlying revenue growth of around 5% (around 5.7% at 31 Oct FX) and a trading profit margin of 19.0%–20.0% versus 18.1% in 2024. Free cash flow guidance was raised to around $750 million, supported by working capital discipline and efficiencies under the 12‑Point Plan. A $500 million share buyback was completed on 7 October 2025.
Management noted a 2025 tariff headwind of $15–$20 million and a 2026 Group margin impact of 25–50bps from US Medicare skin substitute reimbursement changes. Capital Markets Days are scheduled for 8 and 11 December 2025, with full-year results on 2 March 2026.
Smith & Nephew plc reported its latest voting rights and share capital. As of 31 October 2025, total issued share capital comprises 877,724,845 ordinary shares of US20¢ each, including 29,017,524 ordinary shares held in treasury.
With one vote per share, the Company’s issued share capital carrying voting rights consists of 848,707,321 ordinary shares. Shareholders should use this figure as the denominator when assessing disclosure thresholds under the FCA’s Disclosure Guidance and Transparency Rules.
Smith & Nephew plc filed a Form 6-K reporting a TR-1 notification of major holdings. The filing shows BlackRock, Inc. crossed a disclosure threshold, with a total voting interest of 7.18%, comprising 5.01% voting rights attached to shares and 2.17% through financial instruments.
BlackRock held 61,135,065 total voting rights in the issuer at the time the threshold was reached. The position includes 42,555,501 indirect voting rights in shares (5.01%), and financial instruments such as American Depository Receipts (871,572; 0.10%), securities lending (16,864,662; 1.98%), and CFDs (843,330; 0.09%).
Smith & Nephew plc confirmed the sterling amount for its previously announced interim dividend. The dividend of 15.0 US cents per ordinary share will be paid on 7 November 2025 to shareholders on the register at the close of business on 3 October 2025.
Shareholders with a UK address on the register, and those who have validly elected to receive sterling, will receive 11.26 pence per share. This update clarifies the GBP equivalent for eligible holders while the USD amount remains unchanged.
Smith & Nephew plc filed a block listing six monthly return covering 1 February 2025 to 31 July 2025. During the period, the company allotted 206 securities under the Global Share Plan 2010 and 5,758 securities under the Global Share Plan 2020.
Balances not yet issued/allotted at the period end included 3,756 (Global Share Plan 2010) and 403,258 (Global Share Plan 2020). The ShareSave and International ShareSave plans (2012 and 2022) recorded no allotments and maintained prior unallotted balances.
Smith+Nephew plc will publish its third‑quarter 2025 trading report on 6 November 2025 at 7:00am GMT / 2:00am EST. A conference call for financial analysts will follow at 8:30am GMT / 3:30am EST, with access details to be posted on the company’s investor website.
The global medical technology group (LSE: SN; NYSE: SNN) operates across Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management, and reported $5.8 billion in sales in 2024.